-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Turkish Health Minister Koja said on the 3rd that according to the results of the Phase III clinical trial conducted by China Kexing Company in Turkey, the company's new crown vaccine protection rate reached 83.
According to Turkish media reports, Koca quoted relevant data from Turkey's Hatchetpe University to make the above statement at a press conference that day.
Hatchetpe University issued a statement on the 3rd that in the Phase III clinical trial of China Kexing Vaccine, a total of 10216 volunteers were injected with at least one dose of vaccine or placebo.
Starting from September 14 last year, the new crown vaccine developed by China Kexing Company started a Phase III clinical trial in Turkey.
According to data released on the website of the Ministry of Health of Turkey on the 3rd, there were 11,520 new confirmed cases of new crown in the country that day, and a total of 2,734,836 confirmed cases; 65 new deaths and a total of 28,771 deaths.
Leave a message here